George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Is that a fact bothwell - that we have confirmation that an update will be provided soon? Who knows if positive or negative anyway ! We know the most likely
Operational update coming soon…..
Hopefully positive news!
Bothwell,
Because, as I have written many times. They are out of their depth. Not one of the clowns has any pharma experience in sales Marketing or even getting approvals. They are and will always be Miners. They do not realise they have to be very proactive if they want this to work. Previously when RPG was a mining investment platform, they used certain people on the board (now left) to propose mining stocks which they just threw money at. They then sat back and watched as the investment went up or down and then sold. Certainly an easy job and not very demanding on the brain. They obviously think the same strategy could be used when running areal business with a real product....... ERR No.
This is all JM's fault, but unfortunately he didn't know any better since he is just the same.... not much more can be said about incompetence.
They didn’t know…
We have a product that is required my many men around the world and we have approval for many countries at this moment in time and I know we still have the US and China to come. Why has there never been a marketing campaign?
Evening bignose (it's almost10 pm here in blighty) well done for finding it. .makes you wonder why regent didn't seem to know when they announced results in august2022. actually that is a genuine question in a sense , rather that simply another pot at regent. did they not know?could they simply not be bothered to update the announcement? (the wording followed the previous announcement verbatim). whatever the reason it does smack of amateur hour at the office! anyway thanks for finding it. the question though,as you rightly pose, is have there actually been any sales? oh well news before the end of the month.
Found it.
Not necessarily in an RPG announcement but listed in the local HSA website.
5th July 2022.
https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2022
Scroll down to find it.
Morning The,Italian.
If I remember correctly, This was discussed previously here since an import license for Singapore was granted in July, although I would need to go back through my posts to find it.
However. Given the supply originally came from PSNW, I don’t expect they sold many, if any at all. They certainly won’t see many of the 30k cans produced every 4 months if that is all there is available, like the rest of Orients countries supplied.
Yup.
I even told my GP since he said he had a few sufferers coming in each month.
Not that i can see bothwell. the report on 30/8/22 (which is the last reference i can see to singapore) stated "orient is proceeding with obtaining market authorisation in singapore ,philippines, malaysia and brunei". these countries are not, so far as i can see, mentioned again in any official announcements. so what happened? if I've missed something happy to be told so, but if not, it is yet another, to my mind completely unacceptable, example of market being give certain information which is never properly concluded. if it was worthy of inclusion to state the intention to proceed to authorisation,surely the successful completion of that process (or its abandonment or failure) is equally worthy of reporting. anyway,no point me ranting on about it. i no longer,sadly, expect any proper market reporting over and above the necessary statutory requirements re results etc.
It would appear that Fortacin was approved in Singapore on the 5th July 2022, was this covered before?
Who are Endurance RP anyway ???
Of course that should be Q3 2024.....derrr.
Anyone still signing cheques and putting last years date......Ahhh but then again, what are cheques anyway.... lol
I certainly would like to know where they will be getting the money from to bring this to fruition. Q3 2023 maybe only 6 months away (the company should then receive 4mill usd less taxes) but as far as I can see, there is no honey left in the pot.
I also notice from the last years mid year results that they had about 18 people on the books who need paying as well as the building rentals in HK and the UK.
Yes and this was released on 17 April 2023…….
Yes bothwell, painful performance when you read back the enthusiasm in the previous announcements . Needing a drastic change or some honesty about what is going on
Can’t be long until we get an update….
Jamie Gibson, CEO of the Group, said, “We are delighted with the highly significant and positive
results from the Phase 3 clinical study in China, which reinforces the results from the European
and US Phase 3 clinical studies. This represents an important milestone in the regulatory
submission process in China. We now look forward to our commercial partner in China submitting the New Drug Application (“NDA”) to National Medical Products Administration (“NMPA”) by the
end of Q3 2023 with approval expected 12 months later.”
Jamie Gibson further added, “Senstend has the potential to help about 9 million patients in
China during its first year of launch, growing to over 170 million by the tenth year. Our strong
partner Wanbang Biopharmaceutical, who benefits from being part of the Fosun network. This
company has the marketing expertise established e-commerce platforms and an unrivalled
nationwide logic and distribution through Sinopharm, China’s number one pharmaceutical and healthcare distributor, through its network of hospitals, clinics and pharmacies to ensure the
commercial success of Senstend in China.
Heh..that's "happy ex-investor" (admittedly a long time ago). And thank you for "erudite".
Graced with a quietly knowing smile, rather than a smirk, although with the occasional hint of smugness. I do look forward to a few hearty belly laughs on reading the next company update. Parrot-jiggling at its finest.
Send it to Jim and copy Jamie and the company secretary. You are more likely to get a response.
Jim doesn't necessarily always respond, but Jamie usually does after being told by Jim to pull his finger out.
That's from my past experience.
Of course, if you add that JG and the BOD are all incompetent, that will surely get JG's hackles up and he will more than likely respond and probably all in capitals......lol
Sent email to Jamie and Dr Mike a number of weeks ago and no response. They would always respond before.
At least we have one happy non investor who has always displayed erudite and informative negative comments. Always accompanied with a slight smirk me thinks.
What the f**k happened to my capitalisation?
"sell the product outright"...might be difficult when rpg don't have anything to sell. as stated multoties ante, no licensable or transferable intellectual property or commercial protection exists anywhere in the world.
past licences have been simple grants of commercial rights to an approved product. recordati is the de facto mah in europe (and owner of the fortacin trademark), and manufacturing know-how, if any, belongs to them and/or their subcontractor. in the increasingly unlikely event of approval in china (submission stimmied by historical cmc issues, a phantom reference product, and perhaps iffy data and cold feet over market potential), fosun would be the domestic mah and own the registration package.
so, what is in the ple lucky bag? an ind and clinical data package kicked into the long grass by the fda nearly 15 years ago, phase ii pilot data which failed to show any difference between treatment and placebo, the *** end of the recordati agreement, oh, and the orient europharma agreement, although hard to expect a royalty when you can't supply product. and of course that well known senstend trademark...
"remarkable bird, the norwegian blue... beautiful plumage!!
Fair enough bignose. all water under the bridge as they say. been out in the garden this morning spreading some manure ,which in the circumstances here seems very apposite. not sure what brand it was, but something like "mellon's magic" i think! gla.
Morning The.Italian. Not wanting to contradict, but for clarification. The listing was worth 40mill GBP before several dilutions. 40 cents today is, well. A lot lot less than the 40Mill GBP (or was it USD ?....makes no difference still a lot less.). :-)